WelcomeLink to Body ContentLink to Site Map
Select Area of Interest

Choose topic:
Herd/Flock Management
Laws & Regulations
True Cases & Stories
Gallery Graphics
Testing Services
General Information
Biology of Ml. Paratuberculosis
Antimicrobial Therapy
Zoonotic Potential
Test Your Knowledge
Sponsors & Credits

Ask the Expert
Site Map
Search the Site

JOHNE'S INFORMATION CENTER - University of Wisconsin Ñ School of Veterinary Medicine
JOHNE'S INFORMATION CENTER - University of Wisconsin - School of Veterinary Medicine

Search Site

Table Bottom


Comprehensive, reviewed, refreshed and renewed!

Testing Services

Questions about testing?
Call 608-263-6920

What's New    Bar

Thursday, February 15, 2018
MAP DNA detected in 34% of RA samples compared to 8% healthy controls.

Researchers at the University of Central Florida College of Medicine, Orlando, FL hypothesized that Single Nucleotide Polymorphisms (SNPs) in the negative regulators Protein Tyrosine Phosphatase Non-receptor type 2 and 22 (PTPN2/22) lead to a dysregulated immune response, susceptibility to environmental triggers, and continued apoptosis as seen in chronic inflammation in rheumatoid arthritis (RA) and Crohn’s disease (CD).

MAP DNA was detected in 34% of 70 RA patient samples compared to 8% of 48 healthy controls, (p-values ≤ 0.05, OR = 5.74). Combined occurrence of PTPN2:rs478582 and PTPN22:rs2476601 in association with the presence of MAP has significantly increased T-cell response and elevated IFN-γ expression in RA patient samples. The data suggest that genetic polymorphisms may play vital role in T-cell regulation, susceptibility to mycobacteria and ultimately response to treatment. This is the first study to report the detection of MAP DNA in the blood of RA patients; further studies are needed using larger number of samples.

RA is an idiopathic autoimmune disease with suspected genetic predisposition and environmental triggers association. Due to intense inflammation, hyperplasia of the joints occurs along with cartilage and bone destruction, which leads to extreme pain and deformity of the extremities. RA is a common chronic disease that affects about 1% of the world population. The prevalence of RA in the US is estimated at approximately 1.29 million people or 0.6% of the population.

Link to the full article in Frontiers in Cellular and Infection Microbiology


Thursday, February 15, 2018
Vaccination against MAP improves health in a mouse model of MS

Michael R. Warmoth, MD demonstrated that a vaccine targeted against MAP was effective in providing relief from neurologic disability in the EAE mouse model of Relapsing-Remitting Multiple Sclerosis. Peak disability, as measured by the EAE Scoring Parameters, was 38% less (p<0.006) in the SigH immunized mice for the first flare of disability and 40% less (p<0.001) for the relapse.

MS affects approximately 400,000 people in the US and 2.5 million worldwide. In the US, prevalence estimates are approximately 90 per 100,000 population. MS symptoms can start anywhere between 10 and 80 years of age, but onset is usually between 20 and 40 years, with a mean of 32 years. The cause of MS is unknown but thought to result from the interplay of human genetics and unspecified environmental factors.

The MAP vaccine was developed by researchers are the University of Wisconsin-Madison, School of Veterinary Medicine.

Full article


Thursday, January 11, 2018

Pathogenesis, Molecular Genetics, and Genomics of Mycobacterium avium subsp. paratuberculosis, the Etiologic Agent of Johne’s Disease

This excellent review article is a technical summary of what we know about MAP, mainly from the veterinary perspective. It highlights the fecal-oral method of primary transmission, and how MAP causes disease in animals by increasing intestinal permeability and infecting macrophages, which results in granulomas. Diagnostics and current vaccines are discussed, with the caveat that none provide long term immunity. Zoonotic potential is outlined, with a quick overview of published research, and the mapping of the MAP K-10 genome is presented. The article concludes with an in depth discussion of potential vaccines in development and states that live-attenuated vaccines are the best approach against mycobacteria.

This article is available in full on the Frontiers in Veterinary Science journal.


Complete Listing


Back to Top


If you have trouble accessing this site, please contact johnes@vetmed.wisc.edu.

SVM logo